Myriad Genetics to Seek BRCA CDx Approval From Japanese Regulators

GenomeWeb
360Dx
Precision Oncology News

Myriad Genetics to Seek BRCA CDx Approval From Japanese Regulators

Nov 07, 2016

NEW YORK (GenomeWeb) – Myriad Genetics said today that it will submit its BRACAnalysis CDx to Japan's Pharmaceuticals and Medical Devices Agency for regulatory approval, alongside AstraZeneca's PARP inhibitor Lynparza (olaparib).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

Myriad Genetics to Seek BRCA CDx Approval From Japanese Regulators

To read the full story....

Breaking News

USPTO Denies Foundation Medicine Attempt to Invalidate Guardant Health Patent

In Brief This Week: SpeeDx, Abbott

Bio-Techne Gets New York State Approval for Prostate Cancer Test

FDA Issues Draft Recommendations For Biotin Interference Testing

FDA Clears Roche Extraction Platform For Use With Applied BioCode GI Pathogen Panel, System

Invitae Launches Free Genetic Testing Programs With Spark Therapeutics, X4 Pharmaceuticals

Featured White Papers

Clinical Genomics of NTRK Fusion Detection in Cancer

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

What's Popular?

USPTO Denies Foundation Medicine Attempt to Invalidate Guardant Health Patent

BGI Genomics Continues to Grow Clinical Testing Business, Add Partnerships

Bio-Techne Gets New York State Approval for Prostate Cancer Test

ASCO Data Pushes Boundaries for Genomic Testing in Localized Breast Cancer

Invitae Launches Free Genetic Testing Programs With Spark Therapeutics, X4 Pharmaceuticals

Sponsorships